2024-03-29T07:33:53Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1487572017-12-18T14:03:52Zcom_10261_105com_10261_1col_10261_358
2017-04-24T11:47:49Z
urn:hdl:10261/148757
Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease
Podlesniy, Petar
Trullas, Ramón
Ministerio de Economía y Competitividad (España)
Instituto de Salud Carlos III
Federal Ministry of Education and Research (Germany)
Mitochondrial DNA
Cerebrospinal fluid
Creutzfeldt-Jakob disease
Digital PCR
Biomarkers
Alzheimer's disease
Introduction Low content of cell-free mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) is a biomarker of early stage Alzheimer's disease (AD), but whether mtDNA is altered in a rapid neurodegenerative dementia such as Creutzfeldt-Jakob disease is unknown. Methods CSF mtDNA was measured using digital polymerase chain reaction (dPCR) in two independent cohorts comprising a total of 112 patients diagnosed with sporadic Creutzfeldt-Jakob disease (sCJD), probable AD, or non-Alzheimer's type dementia. Results Patients with AD exhibit low mtDNA content in CSF compared with patients diagnosed with sCJD or with non-Alzheimer's type dementias. The CSF concentration of mtDNA does not correlate with Aβ, t-tau, p-tau, and 14-3-3 protein levels in CSF. Discussion Low-CSF mtDNA is not a consequence of brain damage and allows the differential diagnosis of AD from sCJD and other dementias. These results support the hypothesis that mtDNA in CSF is a pathophysiological biomarker of AD.
2017-04-24T11:47:49Z
2017-04-24T11:47:49Z
2016-05
2017-04-24T11:47:50Z
artículo
Alzheimer's and Dementia 12: 546-555 (2016)
http://hdl.handle.net/10261/148757
10.1016/j.jalz.2015.12.011
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/501100002347
eng
Postprint
https://doi.org/10.1016/j.jalz.2015.12.011
Sí
closedAccess
Elsevier